Ab Initio Named Research Collaborator in Tetratherix Precision Medicine Platform
Ab Initio Pharma is pleased to be recognised as a research collaborator by Tetratherix Ltd (ASX: TTX) following the announcement of the company’s new precision medicine franchise and its STEPP nasal drug delivery platform.
The STEPP platform has been under development for more than five years and is designed to enable the nasal delivery of complex biological medicines, including GLP-1 therapies and peptide-based drugs. Delivering fragile biologics without injection presents significant scientific challenges, including enzymatic degradation, poor absorption, and the risk of mucosal irritation or inflammation.
Ab Initio contributed specialist expertise in nasal drug delivery formulation during the platform’s technical validation. Our work focused on supporting the evaluation of STEPP’s performance with challenging biological payloads and helping demonstrate the feasibility of delivering sensitive peptide therapeutics via the nasal route.
This collaboration highlights the growing importance of advanced delivery technologies for biological medicines. As new classes of therapeutics emerge, innovative administration routes such as nasal and inhaled delivery offer the potential to improve patient experience while maintaining therapeutic performance.
Ab Initio specialises in the development of complex dosage forms, particularly inhaled and nasal therapies. The company works at the intersection of formulation science, device development, and regulatory strategy to help partners translate challenging molecules into viable pharmaceutical products.
Further details about the announcement can be found in the Tetratherix ASX release:
